HomeCompareSRGA vs SBUX

SRGA vs SBUX: Dividend Comparison 2026

SRGA yields 1093.49% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SRGA wins by $41252575.48M in total portfolio value
10 years
SRGA
SRGA
● Live price
1093.49%
Share price
$0.18
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41252575.64M
Annual income
$34,962,891,590,796.23
Full SRGA calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — SRGA vs SBUX

📍 SRGA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSRGASBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SRGA + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SRGA pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SRGA
Annual income on $10K today (after 15% tax)
$92,946.97/yr
After 10yr DRIP, annual income (after tax)
$29,718,457,852,176.80/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, SRGA beats the other by $29,718,457,791,710.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SRGA + SBUX for your $10,000?

SRGA: 50%SBUX: 50%
100% SBUX50/50100% SRGA
Portfolio after 10yr
$20626287.91M
Annual income
$17,481,445,830,966.35/yr
Blended yield
84.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

SRGA
Analyst Ratings
4
Buy
1
Hold
Consensus: Buy
Price Target
$3.50
+1813.6% upside vs current
Range: $3.50 — $3.50
Altman Z
-14.1
Piotroski
2/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SRGA buys
0
SBUX buys
0
No recent congressional trades found for SRGA or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSRGASBUX
Forward yield1093.49%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$41252575.64M$167.0K
Annual income after 10y$34,962,891,590,796.23$71,136.45
Total dividends collected$40777781.60M$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy
Analyst price target$3.50$104.00

Year-by-year: SRGA vs SBUX ($10,000, DRIP)

YearSRGA PortfolioSRGA Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$120,049$109,349.37$11,121$420.68+$108.9KSRGA
2$1,355,305$1,226,852.64$12,548$648.40+$1.34MSRGA
3$14,394,696$12,944,519.24$14,440$1,013.98+$14.38MSRGA
4$143,891,771$128,489,446.28$17,068$1,617.30+$143.87MSRGA
5$1,354,339,736$1,200,375,541.00$20,912$2,649.52+$1354.32MSRGA
6$12,008,197,800$10,559,054,282.68$26,875$4,499.29+$12008.17MSRGA
7$100,345,428,030$87,496,656,383.52$36,771$8,014.12+$100345.39MSRGA
8$790,694,806,514$683,325,198,522.44$54,542$15,197.11+$790694.75MSRGA
9$5,878,209,395,115$5,032,165,952,144.85$89,602$31,242.49+$5878209.31MSRGA
10$41,252,575,643,570$34,962,891,590,796.23$167,011$71,136.45+$41252575.48MSRGA

SRGA vs SBUX: Complete Analysis 2026

SRGAStock

Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spine implants worldwide. It offers products for thoracolumbar procedures, including Streamline TL Spinal Fixation system, a system for degenerative and complex spine procedures; and Streamline MIS Spinal Fixation system, a range of implants and instruments used via a percutaneous or mini-open approach; and interbody fusion devices, as well as products for cervical procedures, such as CervAlign ACP system, a comprehensive anterior cervical plate system; Fortilink-C IBF system, a cervical interbody fusion device that utilizes TETRAfuse 3D technology; and Streamline OCT system, a range of implants used in the occipito-cervico-thoracic posterior spine. The company also provides motion preservation systems comprising Coflex Interlaminar Stabilization device for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; HPS 2.0 Universal Fixation system, a pedicle screw system used for posterior stabilization of the thoracolumbar spine; and SImmetry SI Joint Fusion system, a minimally invasive surgical implant system to decrease opioid use, pain, and disability. In addition, it develops Augmented Reality and Artificial Intelligence digital surgery platform to enable digital spine surgery. The company markets its products through independent spine and biomaterial distributors to hospitals, ambulatory surgery centers, and healthcare providers, as well as through direct sales force. The company was incorporated in 1997 and is headquartered in Deerfield, Illinois.

Full SRGA Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this SRGA vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SRGA vs SCHDSRGA vs JEPISRGA vs OSRGA vs KOSRGA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.